Vivimed Labs Limited
NSE: VIVIMEDLAB
NSE
4.95
0.00 (0.00%)
Prev Close
4.95
Open Price
5.25
Volume
151,690
Today Low / High
4.85 / 5.25
52 WK Low / High
4.85 / 5.25
Range
5 - 5
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 4.95, with a change of 0 (0%). The expected target range on the NSE is between 5 - 5. The stock is trending upwards on the NSE, which could present a good opportunity for potential investors.
Vivimed Labs Limited Graph
Vivimed Labs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Vivimed Labs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 4.95, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 4.95 | 5.00 | 4.50 - 5.50 |
| 5.05 | 4.04 - 6.06 | ||
| 5.10 | 3.57 - 6.63 | ||
| Bearish Scenario | 4.95 | 4.90 | 4.41 - 5.39 |
| 4.85 | 3.88 - 5.82 | ||
| 4.80 | 3.36 - 6.24 |
Overview of Vivimed Labs Limited
ISIN
INE526G01021
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
0
Market Cap
410,423,840
Last Dividend
0
Official Website
IPO Date
2005-08-17
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of VIVIMEDLAB
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2018-09-19 | September 19, 18 | 0.4 | 0.4 | 2018-09-21 | 2018-10-26 | 2018-05-30 |
| 2017-09-21 | September 21, 17 | 0.4 | 0.4 | 2017-09-22 | 2017-10-29 | 2017-05-28 |
| 2014-09-24 | September 24, 14 | 0.6 | 3 | 2014-09-25 | 2014-10-29 | 2014-05-30 |
| 2013-09-24 | September 24, 13 | 0.6 | 3 | 2013-09-25 | 2013-10-30 | 2013-05-31 |
| 2012-09-21 | September 21, 12 | 0.6 | 3 | 2012-09-24 | 2012-10-27 | 2012-05-31 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 116.27 Cr | 108.47 Cr | 7.80 Cr | 0.0671 | 0.00 Cr | 0.00 Cr | -33.27 Cr | -31.96 Cr | -3.85 | -8.68 Cr | -0.2749 |
| 2024-03-31 | 149.07 Cr | 78.50 Cr | 70.57 Cr | 0.4734 | 0.21 Cr | 6.11 Cr | -14.81 Cr | -45.45 Cr | -5.48 | -24.67 Cr | -0.3049 |
| 2023-03-31 | 187.10 Cr | 279.96 Cr | -92.87 Cr | -0.4963 | 0.27 Cr | 20.55 Cr | -121.82 Cr | -328.53 Cr | -39.62 | -185.92 Cr | -1.7559 |
| 2022-03-31 | 237.29 Cr | 153.48 Cr | 83.80 Cr | 0.3532 | 0.34 Cr | 14.02 Cr | -25.07 Cr | -67.65 Cr | -8.16 | -6.79 Cr | -0.2851 |
| 2021-03-31 | 861.47 Cr | 354.53 Cr | 506.94 Cr | 0.5885 | 26.44 Cr | 0.00 Cr | -6.85 Cr | -77.80 Cr | -9.38 | 33.61 Cr | -0.0903 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.71 Cr | 920.83 Cr | 956.00 Cr | -35.1690 Cr | 376.33 Cr | 375.62 Cr | 58.76 Cr | 271.52 Cr | 0.00 Cr | 0.00 Cr | 168.50 Cr | 408.1970 Cr |
| 2024-03-31 | 1.63 Cr | 950.91 Cr | 956.37 Cr | -5.4610 Cr | 378.79 Cr | 377.16 Cr | 64.06 Cr | 283.51 Cr | 0.00 Cr | 0.00 Cr | 168.50 Cr | 410.3260 Cr |
| 2023-03-31 | 3.76 Cr | 988.34 Cr | 948.92 Cr | 39.4230 Cr | 381.03 Cr | 377.27 Cr | 79.76 Cr | 298.84 Cr | 8.83 Cr | 0.00 Cr | 198.82 Cr | 424.3000 Cr |
| 2022-03-31 | 7.18 Cr | 1,266.02 Cr | 901.73 Cr | 364.2861 Cr | 278.33 Cr | 271.15 Cr | 240.77 Cr | 402.60 Cr | 111.64 Cr | 449.63 Cr | 198.82 Cr | 373.7575 Cr |
| 2021-03-31 | 6.43 Cr | 1,289.33 Cr | 857.75 Cr | 431.5763 Cr | 252.67 Cr | 246.24 Cr | 255.68 Cr | 408.26 Cr | 111.19 Cr | 445.29 Cr | 198.82 Cr | 341.4406 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -4.0970 Cr | -4.5310 Cr | 7.3100 Cr | -8.6280 Cr | -1.3180 Cr | 0.7080 Cr | -4.5310 Cr | -31.9610 Cr | 7.3100 Cr | 0.0000 Cr | 5.3070 Cr |
| 2024-03-31 | -23.9910 Cr | 28.2880 Cr | -6.0320 Cr | -26.0300 Cr | -1.7360 Cr | 2.0260 Cr | -2.0390 Cr | -45.4460 Cr | -3.6000 Cr | 0.0000 Cr | 15.6980 Cr |
| 2023-03-31 | 13.8120 Cr | -4.9680 Cr | -16.2440 Cr | 30.3540 Cr | -3.4220 Cr | 3.7620 Cr | -4.9680 Cr | -330.6510 Cr | 2.1210 Cr | 0.0000 Cr | 161.0060 Cr |
| 2022-03-31 | -658.4683 Cr | 523.3400 Cr | -10.3800 Cr | -674.8783 Cr | 93.1200 Cr | 99.5500 Cr | -16.4100 Cr | -64.2748 Cr | 6.9260 Cr | 0.0000 Cr | 159.8800 Cr |
| 2021-03-31 | 567.2758 Cr | 403.9988 Cr | -1,015.3318 Cr | 567.2758 Cr | -44.0572 Cr | 6.4313 Cr | 0.0000 Cr | -75.7659 Cr | -636.2350 Cr | 0.0000 Cr | 246.2247 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 21.39 Cr | 9.80 Cr | 11.59 Cr | 0.5419 | -5.30 Cr | -5.49 Cr | -0.66 | 0.10 Cr | -0.2568 |
| 2025-03-31 | 25.61 Cr | 25.73 Cr | -0.12 Cr | -0.0046 | -7.96 Cr | -5.60 Cr | -0.67 | 1.75 Cr | -0.2186 |
| 2024-12-31 | 36.51 Cr | 19.69 Cr | 16.82 Cr | 0.4608 | -5.56 Cr | -5.98 Cr | -0.72 | 1.12 Cr | -0.1637 |
| 2024-09-30 | 24.77 Cr | 11.37 Cr | 13.41 Cr | 0.5412 | -4.74 Cr | -5.14 Cr | -0.62 | -0.61 Cr | -0.2075 |
| 2024-06-30 | 29.37 Cr | 17.36 Cr | 12.02 Cr | 0.4092 | -15.01 Cr | -15.25 Cr | -1.84 | -10.94 Cr | -0.5190 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.71 Cr | 0.00 Cr | 0.71 Cr | 121.04 Cr | 58.76 Cr | 327.55 Cr | 271.52 Cr | 920.83 Cr | 956.00 Cr |
| 2024-09-30 | 1.58 Cr | 73.22 Cr | 74.80 Cr | 38.82 Cr | 60.64 Cr | 338.98 Cr | 280.70 Cr | 943.29 Cr | 969.14 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 1.63 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 5.46 Cr |
| 2024-03-31 | 1.63 Cr | 70.15 Cr | 71.78 Cr | 41.42 Cr | 64.06 Cr | 342.58 Cr | 283.51 Cr | 950.91 Cr | 956.37 Cr |
| 2023-12-31 | -2.28 Cr | 4.55 Cr | 2.28 Cr | 0.00 Cr | 0.00 Cr | 2.28 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | -0.01 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -0.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 0.01 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | -16.05 Cr | 9.41 Cr | 0.00 Cr | 0.00 Cr | 9.41 Cr | 11.69 Cr | 2.28 Cr | 0.00 Cr | 9.41 Cr |
| 2023-09-30 | -20.30 Cr | 9.41 Cr | 0.00 Cr | 0.00 Cr | 9.41 Cr | 2.28 Cr | -7.13 Cr | 0.00 Cr | 9.41 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2016-04-06 | April 06, 16 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,654.70 | ₹3,970,173,579,881.00 | ₹1,756,767.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,826.50 | ₹1,546,757,529,018.00 | ₹196,212.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,526.00 | ₹1,193,357,070,000.00 | ₹376,267.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,248.60 | ₹1,039,299,991,350.00 | ₹1,880,883.00 |
| Mankind Pharma Limited | MANKIND | ₹2,456.30 | ₹1,013,858,678,987.00 | ₹377,582.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹994.65 | ₹1,000,846,232,849.00 | ₹364,823.00 |
| Lupin Limited | LUPIN | ₹1,937.30 | ₹884,877,017,676.00 | ₹1,001,317.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,494.00 | ₹656,890,110,000.00 | ₹106,173.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,096.50 | ₹636,848,979,620.00 | ₹645,374.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,971.80 | ₹556,443,555,186.00 | ₹346,577.00 |
| Laurus Labs Limited | LAURUSLABS | ₹863.00 | ₹465,868,887,837.00 | ₹1,494,281.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,323.20 | ₹335,701,421,258.00 | ₹85,707.00 |
| Cohance Lifesciences Limited | COHANCE | ₹869.70 | ₹332,718,641,658.00 | ₹155,406.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,431.30 | ₹303,755,982,631.00 | ₹100,950.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.80 | ₹259,761,841,253.00 | ₹270,889.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,414.50 | ₹235,362,500,000.00 | ₹23,894.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,429.20 | ₹232,223,277,589.00 | ₹428,259.00 |
| Eris Lifesciences Limited | ERIS | ₹1,607.20 | ₹218,922,423,989.00 | ₹47,179.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,106.00 | ₹193,808,303,234.00 | ₹19,762.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹906.35 | ₹178,154,987,437.00 | ₹67,592.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,096.70 | ₹173,882,644,813.00 | ₹72,025.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,021.40 | ₹153,650,042,294.00 | ₹42,984.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹815.15 | ₹146,001,410,531.00 | ₹337,915.00 |
| Granules India Limited | GRANULES | ₹552.70 | ₹134,109,181,833.00 | ₹549,140.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,201.00 | ₹102,932,767,782.00 | ₹16,453.00 |
| Strides Pharma Science Limited | STAR | ₹834.10 | ₹76,881,260,747.00 | ₹283,085.00 |
| FDC Limited | FDC | ₹465.65 | ₹75,812,515,615.00 | ₹113,533.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹829.95 | ₹75,220,832,622.00 | ₹152,926.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹377.45 | ₹73,822,356,449.00 | ₹119,629.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.29 | ₹50,554,870,224.00 | ₹683,471.00 |
| Innova Captab Limited | INNOVACAP | ₹832.25 | ₹47,625,447,160.00 | ₹23,268.00 |
| Suven Life Sciences Limited | SUVEN | ₹209.40 | ₹45,657,721,952.00 | ₹147,288.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹499.30 | ₹45,571,111,000.00 | ₹135,801.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹131.91 | ₹42,807,642,673.00 | ₹181,574.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹742.50 | ₹37,658,935,463.00 | ₹61,065.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,252.40 | ₹37,252,477,386.00 | ₹5,835.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹354.70 | ₹35,570,204,878.00 | ₹16,230.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹487.00 | ₹34,287,600,250.00 | ₹11,723.00 |
| Hikal Limited | HIKAL | ₹253.10 | ₹31,207,419,825.00 | ₹196,519.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹103.87 | ₹30,488,702,464.00 | ₹1,844,372.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹48.73 | ₹26,701,783,752.00 | ₹1,385,993.00 |
| Alembic Limited | ALEMBICLTD | ₹102.14 | ₹26,227,695,912.00 | ₹175,157.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹612.00 | ₹26,173,985,400.00 | ₹53,814.00 |
| Indoco Remedies Limited | INDOCO | ₹284.00 | ₹26,173,839,020.00 | ₹31,975.00 |
Key Executives
Chief Executive of Uquifa - Vivimed's API Division
Mr. Mark I. Robbins
Gender: male
Year Born:
Whole Time Director
Dr. Manohar Rao Varalwar
Gender: Not Specified
Year Born: 1936
Compliance Officer & Company Secretary
Mr. Yugandhar Kopparthi
Gender: male
Year Born:
Executive Director
Mr. Sandeep Varalwar B.Pharma
Gender: male
Year Born: 1968
MD & Executive Director
Mr. Santosh Varalwar
Gender: male
Year Born: 1962
FAQs about Vivimed Labs Limited
Who is the CEO of the company?
The CEO is Santosh Varalwar.
What is the current market price of the stock?
The current price is ₹4.95.
What is the 52-week price range?
The range is ₹4.85-5.25.
What is the market capitalization of the company?
The market capitalization is ₹41.04 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is -1.85.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Vivimed Labs Limited (ISIN: INE526G01021) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹41.04 crores and an average daily volume of 0 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.